Member Info for LovableLumax

Back end of the year

Yep, the fact they have said in a regulated RNS they have dosed multiple patients and outlined the 3 indications there is no way STS has been dropped. The question is why would they delete from their timeline which I assume means they will not be taking it into P2 but someone else will. If they were just going to drop it they would do so now but after spending time and money on P1b. The question is what kind of deal and what triggers it (complete P1b data or emerging?).

Https://x.com/rah00084/status/1900079967897051585?s=46

That’s the thing. It’s a delivery system and they haven’t modified dox at all so the same molecule is dumped at the tumour site. The MoA is proven and dos is behaving like dox. Every single biopsy has shown the MoA is robust, no MTD found and signs of efficacy is many different tumour types.

Dox is now reaching new heights as so much is dumped at tumour site, smashing CAFs as bystander effect is meaning disease can still regress after treatment. Surely emerging P1b will be superb. I’m hoping most of the patients dosed so far are SGC patients as who knows how quickly that could move.

I'm just giving an alternative view. Potential has always been massive and we'll know if they're turned a corner soon enough. Have a good weekend.

LOTM you have a short memory. A little over 12 months ago you invested and sold the story on other BBs while I cautioned that the audit would need a cash injection and you said it was BS and phevs even said break even near. A little while later you were on here and advfn apologising after a 40% discounted raise announced. Anyway, we'll see if history repeats. I suspect Dr Milner has a better view than you and he like the other TR1s were selling

I may be wrong but I can see history repeating. LOTM will be back on here apologising for getting people to invest when a discounted raise is announced within 2 months.

The cost base so £8m pa but that just means in the year costs will be £667k a month but when that happens who knows. If say Q3 it’s reduced to £667k that means the costs pa are £8m. Do you get it?!

They said the costs will be £8m pa but they did not say when they will achieve that ie they could get to £667k costs in H2.

Q4 last year the costs were £2.25m or £9m pa.

FYI as at Dec 31 2023 they had £6.1m cash and as at Dec 31 2024 they had £4.8m. Yes costs have been reduced but unless revenues a lot higher they need cash. No material RNSs so that’s why Milner and others have been selling. They reduced cash burn to £750k a month in Q4 and this year the costs will come down to £8m but who knows when the monthly burn rate will be down to £667K. Anyway, I may be wrong but look at last year when the share price was increasing and bang the 40% discounted raise RNS came.

My other AiM holding has the same issue.

wow, i cannot be ****d to read that. all i would caution is that in sept mirriad signed off a broker note saying programmatic would be launched by year end and fy25 was a £4m loss. we are in march and programmatic not launched and every single guidance ever issued has been a lot worse so safe to assume a £4m loss will be higher.

mirriad had more cash last year and worked on a raise in april as they needed cash for audit sign off on june. h1 always very slow so they are likely to be running on fumes soon and will surely be working on a raise in the coming weeks. mirriad has worked with pepsi co and many household names for years but the issue is monetising. the only tr1s we have had since the raise have been 4 reductions. the next couple of rnss key.

Https://x.com/asininitybeyond/status/1897282817752752419?s=46

The Diagnostics Division has continued to grow revenues, with the sale of Coris products through the Launch Diagnostics ('Launch') distribution channels and the expansion of Launch into the German market. The Company streamlined its operations during the period by closing its Wetherby facility, having transferred product development activities to the Coris operations in Belgium. Revenues have grown to £11.2 million in the six-month period ended 30 June 2024, from £9.9 million in the same period to 30 June 2023. This has led to an improvement in adjusted EBITDA to £0.1 million in the six-month period ended 30 June 2024, from an EBITDA loss of £0.4 million in the comparative period in 2023. The Company expects the Diagnostics Division to remain adjusted EBITDA positive in H2 2024 and be cash flow positive in 2025.

Decent growth and if Avacta gets £20m yes it's an ugly loss but should mean audit sign off and able to attract specialist investors. I suspect if they sell and confirm audit will be signed off, P1b has started and recrtuitment is going well and read out still H2 the share price will recover and the conversions will be much less of a drag.

The Clinical Diagnostics Market size is estimated at USD 88.79 billion in 2025, and is expected to reach USD 115.94 billion by 2030, at a CAGR of 5.48% during the forecast period (2025-2030). Key drivers fuelling the expansion of the clinical diagnostics market include rising cases of infectious and chronic diseases, a surge in the adoption of automated platforms, and improved access to healthcare services for the general populace. Source: https://www.mordorintelligence.com/industry-reports/clinical-diagnostic-market

Https://x.com/rah00084/status/1896236391157354608?s=46

I suspect the reason people aren’t buying is because of what happened in April last year and the year before. A raise. Mirriad has less cash now than both those years. Before those raises we had many super LinkedIn posts with new brands and yet revenue fell and strategic partners fell. Who knows maybe this year is different but the lack of material RNSs (like the last 2 years) doesn’t bode well. Assuming come April mirriad has £3.3m cash left (assume costs of £2m and revenue of £500k which is more than entire H1 last year) they will surely work on a raise as they did previously. Question is how much to satisfy the auditor and what discount. That’s why volume isn’t picking up. Phevs sold 6m to give himself 6 months more cash, more than MIRI has. Phevs like the other 4 TR1s, reducing holding.

I’m always happy to admit when I’m wrong. No issue at all.

I don’t recall ever saying mirriad wasn’t working with GM or WBD, why would I? I think you’ve made that up.

You were suggesting mirriad could have lots of cash from US elections and the opposite occurred they blamed that on their awful revenue. Did you apologise? Many other examples but hey. As far as I can see everything I have predicted for 12 months has been accurate. Prior to that I had an awful record here as thought mirriad close to turning a corner.

Mirriad has an amazing number of brands it works with and has for many years. The issue has always been monetising.

Of course mirriad may launch programmatic imminently and may sign some large contracts for the auditor to see. Let’s see.

I'm relaxed and find it funny how a different view which has substance gets some people to have hissy fits as they want a happy clapper BB without opposing views. Yes they need to have sufficient cash to see them through 12 months from the audit sign off. Of course if they had X £m of signed orders this would reduce the cash needed. The point it MIRI has missed every guidance it has ever issued so their revenue forecast (cash coming in) means little. Ayyway, we'll see if I'm right and we'll know by end of April IMO

The reason there is no RNS is because the campaigns are not deemed material so are not excpected to contribute 10% of last year's revenue (£100k). MIRI has worked with huge brands for years and has run many campaigns (look at the KPIs) but the revenue per campaign is minimal as the revenues demonstrate.

The LinkedIn pumping continues. I have other investments and only one other AIM listed, AVACTA which is comimg under pressure as eveyone knows a raise is needed to have the audit signed off and the same applies here. MIRI is nearly 3p which is likely near to its cash position (end of March likely will be £3m) and last year they raised when they had more than £3m cash and the same seems inevitable. New guidance will be issued soon but last Sept had programmatic ready at YE and a £4m FY25 loss guided, MIRI has always missed guidance so that will surely be worse and the audit will want them to have cash for a year so a a raise inevitable. With limited forward orders it's a question of how much will be new auditor insist they have to see them through to June next year

Indeed Sammy, given the withpower is deemed fairly accurate (it wouldn't be used if not!) they wouldn't have screened end of last year (takes 3 weeks) and not started. Something might be holding back an RNS but I don't think it's that P1b hasn't started, I expect we get a comprehensive RNS soon which will hopefully include the trial designs too.